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ABSTRACT

SND1-TARGETED GENE THERAPY FOR HEPATOCELLULAR CARCINOMA
By BRYAN D. MCKIVER, B.S.
A thesis submitted in partial fulfillment of the requirements for the degree of
Master of Science Virginia Commonwealth University, 2018
ADVISOR: DR. DEVANAND SARKAR, M.B.B.S., Ph.D
Professor, Department of Human and Molecular Genetics
Harrison Foundation Distinguished Professor in Cancer Research
Virginia Commonwealth University

Staphylococcal nuclease and tudor-domain containing 1 (SND1) is an oncogene for a
wide variety of cancers, including hepatocellular carcinoma (HCC). SND1 is a
multifunctional protein regulating gene expression of proto-oncogenes and tumor
suppressor genes, making SND1 a prime target for developing cancer therapeutics.
This notion is especially attributed to HCC as most patients are diagnosed in advanced
stages and the therapeutic options available for these patients are severely limited. In
this study, we evaluated the therapeutic potential of a replication-defective adenovirus
vector delivering SND1 shRNA (Ad.SND1sh) to human HCC cell lines, HepG3, HuH-7,
and Hep3B. Adenovirus infection in HCC cells was confirmed by Western blotting and
immunofluorescence. The efficacy of Ad.SND1sh to knockdown SND1 expression was
confirmed via Western blot, qRT-PCR, and immunofluorescence. Ad.SND1sh did not
significantly affect proliferation of the three human HCC cells but significantly inhibited
their invasive and migratory capacities, as determined by wound healing and Matrigel
invasion assays, respectively. As a corollary, Ad.SND1sh treatment resulted in a
decrease in mesenchymal markers, such as N-cadherin, Twist, Snail, and Slug, without

viii

affecting levels of epithelial marker E-Cadherin, indicating that SND1 knockdown
induces mesenchymal conversion in HCC cells. Additionally, reductions in liver cancer
stem cell marker CD133 and HCC marker α-fetoprotein (AFP) were observed with
SND1 knockdown. HCC cells with aberrant expression of these markers are associated
with tumor initiation, recurrence, and multi-drug resistance. Our findings indicate that
Ad.SND1sh may potentially be an effective therapy for advanced HCC and needs to be
studied further for its clinical application.
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CHAPTER 1
INTRODUCTION
HEPATOCELLULAR CARCINOMA
Hepatocellular Carcinoma (HCC) is characterized as the development of malignant
tumors from liver hepatocytes. HCC is the most common form of primary liver cancer
and is the second most common leading cause of cancer related death worldwide, with
nearly half a million new cases being diagnosed annually1. According to GLOBOCAN
2012 HCC is the fifth most common cancer in men, globally, and the seventh most
common among women.
HCC INCIDENCE
The global incidence rates of patients diagnosed with HCC vary depending on
geographical location. Regions with endemic HBV infection rates (prevalence ≥8%),
such as Sub-Saharan Africa and Eastern Asia, have incident rates as high as 20 per
100,000 individuals being diagnosed with HCC annually2.
The number of patients diagnosed with HCC appears to be on the rise in the United
States (US). An analysis of Surveillance Epidemiology and End Results (SEER)
registries based on population data showed that the annual age-adjusted incidence
rates of HCC have doubled from 1977 to 2007.3 With an overall 5-year survival rate of
˂12%, HCC is quickly becoming one leading causes of cancer-related death in the US2.
HCC RISC FACTORS
Development of HCC has been shown to be comorbid with liver cirrhosis, as 80% to
90% of HCC cases occur in a cirrhotic liver setting4. Liver cirrhosis is defined as the
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progressive loss of proliferative capacity in hepatocytes and the development of fibrotic
scar tissue (fibrosis) that ultimately leads to portal hypertension and end-stage liver
disease5.
50% of HCC cases occur in individuals infected with Hepatitis B Virus (HBV), making it
the leading risk factor for HCC worldwide6. HBV is hepatotropic, enveloped, partially
double-stranded DNA virus belonging to the Hepadnaviridae family. HBV is
characterized as an oncovirus primarily due to its ability to integrate its genome into
host DNA leading to the development of mutations, causing chromosomal instability,
and alterations to host gene expression7. Additionally, chronic HBV infection induces a
sustained inflammatory response8, which has a high probability of causing cirrhosis and
leading to the development of HCC9. However, HBV infection has been shown to
directly correlate with HCC development in the absence of cirrhosis10.
Hepatitis C virus (HCV) infection is another risk factor associated with HCC
development and accounts for up 25% of HCC cases in Asia and Africa, and 60% of the
cases in the US11. HCV is an enveloped RNA virus which is incapable of host genome
integration7. Hence, HCV infection leads to HCC development exclusively in a setting of
liver cirrhosis. HCV infection produces core viral proteins in liver hepatocytes that
promote tumorigenesis via interaction with host cell factors involved in apoptosis, DNA
replication, DNA repair, cell cycle progression, and angiogenesis12. Both HBV and HCV
are involved in the initiation and progression of HCC through alterations in DNA repair
systems, centrosome duplication mechanisms, and disruption of gene expression and
signaling pathways9.
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Chronic alcohol consumption represents another HCC risk factor. Alcohol consumption
has been shown to lead to severe liver damage and disease via oxidative stress and
inflammation13. Chronic alcohol consumption can also be a cofactor in other HCC risk
factors to increase likelihood of HCC development. In one study, patients with HBVinduced cirrhosis, heavy drinking was found to triple their risk of HCC development 14.
Another HCC risk factor is Non-Alcoholic Fatty Liver Disease (NAFLD), which is the
process by which fatty tissue accumulates in the liver, leading to cirrhosis. NAFLD is
currently the leading cause of chronic liver disease in the US 2. A population study
analyzing SEER-Medicare database revealed a statistically significant correlation
between HCC and metabolic syndrome, a disease which shares similar phenotypes
with NAFLD15. Aflatoxin exposure is another risk factor of HCC16.
HCC TREATMENTS
Liver transplantation and resection are the two most common treatments for HCC17.
Liver Transplantation being the optimum choice for patients with advanced cirrhosis18,
and liver resection is best for patients with noncirrhotic functional livers19. Local ablation
using radiofrequency is currently the standard form of care for patients with early stage
tumors (˂4cm) and has been shown to provide higher recurrence-free survival rates
compared to that of percutaneous ethanol ablation20. Transcatheter arterial
chemoembolization (TACE) involves the administration of a chemotherapeutic drug and
embolization agent directly to a liver tumor through a catheter, with the goal of
restricting tumor blood supply and increasing tumor exposure to chemotherapeutics 17.
TACE treatment is typically reserved for patients with HCC liver that lacks vascular
invasion and is deemed unresectable17. Currently, Sorafenib is the only FDA approved
3

first line systemic treatment for HCC21. Sorafenib is a monoclonal antibody that acts as
a tyrosine kinase inhibitor, targeting a multitude of cell surface receptors and
downstream signaling modulators involved in tumor progression. In the Phase III
Sorafenib HCC Assessment Randomized Protocol (SHARP) study, 602 patients with
advanced HCC were randomized and administered either 400 mg of sorafenib or
placebo22. The median overall survival of the sorafenib group in the SHARP trial was
10.7 months, which is a significant increase when compared to 7.9 months of the
placebo group22. Like most other chemotherapeutics, Sorafenib treatment causes some
negative side effects in patients. Adverse effects noted in the SHARP study include:
diarrhea, fatigue, hand-foot skin reaction, rash, alopecia, hypophosphatemia,
thrombocytopenia, and hypertension22. Regorafenib, a multi-kinase inhibitor, and
nivolumab, a PD-1 check point inhibitor, are FDA approved monoclonal antibodies used
as second line treatments for HCC after sorafenib progression23,24. The increasing
global incidence of HCC combined with the lack of FDA approved mid-to-late stage
treatment options makes the identification of novel therapeutic targets in HCC of critical
concern.
SND1 STRUCTURE AND FUNCTIONS
In humans the SND1 gene is located on chromosome 7q31.3, with this region having
been shown to undergo amplification in a variety of cancers25-27. The protein translated
from this gene, Staphylococcal nuclease and tudor-domain containing 1 protein (SND1),
contains four tandemly repeated staphylococcal nuclease (SN) domains and a fifth
domain with tudor and nuclease (TSN) fusion activity28. Like most
oligonucleotide/oligosaccharide binding (OB) fold proteins which lack enzymatic activity,
4

the SN domains of SND1 lack the amino acid residues required to facilitate the calciumdependent thermonuclease activity that is commonly observed in SN domains29-31. OB
fold proteins, like SND1, are reported to be involved in a multitude of cellular processes,
such as transcriptional activation or repression, DNA repair, and chromatin
modification29. As for the tudor domain, its presence has been well documented in
proteins that interact with DNA, with specific functions related to epigenetic regulation,
gene expression, and the biogenesis of regulatory RNA molecules (snRNP, miRNA,
and siRNA)31. SND1 has been shown to be highly overexpressed in a large percentage
of HCC patients, and is used as a marker to denote tumor stage progression32. The
correlation between SND1 protein abundance and tumor progression appears to be a
result of its ability to regulate gene expression of proto-oncogenes and tumor
suppressor genes33.
SND1 plays an important role in transcriptional regulation, as it was initially identified as
a transcriptional co-activator in a study attempting to identify proteins that interact with
Epstein-Barr nuclear antigen, where it was shown to directly interact with EBNA234. As a
transcriptional co-activator, SND1 has been shown to interact with transcription factors
(TFs) such as STATs35,36 and SMAD37 family proteins which, respectively, leads to an
increase in Janus kinases (JAK) and Transforming Growth Factor Beta (TGFβ)
downstream signaling35-37.
SND1 IN HCC
SND1 associates with Astrocyte Elevated Gene-1 (AEG1), another HCC oncogene, and
other proteins to form a stable RNA-induced silencing complex (RISC) where SND1
functions as a nuclease. RISC interacts with either a single strand of small interfering
5

RNA (siRNA) or micro RNA (miRNA) and uses them as templates for targeting and
suppressing complementary mRNA. This interaction facilitates the role of SND1 in
modulating post-transcriptional gene expression.32,38
It has been shown that SND1 can interact directly with mRNA in a manner that is
independent of its role in RISC. In one study, it was revealed that SND1 stabilizes
mRNA transcripts of angiotensin II type 1 receptor (AT1R) by binding to its 3’UTR,
leading to increased AT1R protein production and downstream signaling39. Additionally,
we showed that stable knockdown of SND1 in human HCC cell lines resulted in a
reduction of AT1R expression leading to decreased expression of TGFβ and its
downstream signaling genes40. In the same study, SND1 was also stably over
expressed in HCC cells leading to increased TGFβ signaling and activation of
Plasminogen Activator Inhibitor- 1 (PAI-1), which promotes tumor migration and
invasion41.
In vitro studies have shown that SND1 plays an integral role in the development of HCC
by affecting cellular proliferation, migration, invasion, angiogenesis, and epithelialmesenchymal transition (Fig. 1). These results lead to the development of a transgenic
mouse model (Alb/SND1) expressing Myc-tagged human SND1 under an albumin
promoter with a B6CBAF1 background. The goal of this model was to understand how
overexpression of SND1 in liver hepatocytes influenced HCC development in vivo41. To
stimulate liver carcinogenesis, the mice received a single intraperitoneal injection of Nnitroso-diethylamine (DEN) at a dosage of 10 μg DEN/gram of body weight at 14 days
of age, with their livers being harvested at 32 weeks of age 41. The results of this study
corroborated that Alb/SND1 mice injected with DEN developed robust tumorigenic
6

responses in the liver at 32 weeks of age, when compared to WT littermates injected
with DEN41. An increase in mRNA levels of TNFα and c-myc, key HCC drivers, was
detected as early as 2 months of age, with increased IL-6 levels at 12 months of age41.
Western blot analysis using anti-SND1 and anti-Myc-Tag antibodies were used to
confirm overexpression of SND1 in Alb/SND1 compared to WT littermates 41. AFP and
CD36 (HCC markers), CD31 (angiogenesis marker), and PCNA (proliferation marker)
were also detected at higher levels in DEN-Alb/SND1 mouse livers compared to DENWT littermates41. An increase in activated NFκB, ERK, Akt, and GSK3β was
established in both Alb/SND1 and DEN-Alb/SND1 mice, indicating that these genes are
constitutively active in SND1 overexpressing liver tissue41. Hepatocytes isolated from
Alb/SND1 mouse livers were able to form proliferative spheres when cultured in ultralow
attachment plates and expressed high levels of Tumor Initiator Cell (TIC) markers
EpCAM, CD44, and CD13341. Treatment with the drug pdTp, which binds the SN
domains of SND1 inhibiting its enzymatic activity, resulted in significantly reduced
sphere formation and TIC marker protein levels in both Alb/SND1 and WT hepatocytes
compared to vehicle treated controls. This indicates that SND1 enzymatic activity is
necessary to facilitate TIC expansion in liver hepatocytes41. Additionally, inhibition of
NFκB and Akt phosphorylation was observed in pdTp treated Alb/SND1 hepatocytes,
with ERK phosphorylation being unaffeceted41. It was found that pdTp treatment did not
reduce AT1R mRNA levels, which was previously found to stimulate TGFβ signaling
leading to ERK activation40, 41. Demonstrating that SND1 binds the 3’-UTR of mRNA
transcripts independent of its enzymatic activity41. This data stands to further validate
the novelty of SND1 targeted therapy as a means for potentially treating HCC.
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EPITHELIAL-MESENCHYMAL TRANSITION
Epithelial-Mesenchymal Transition (EMT) is a complex biological process by which
epithelial cells, which are characterized by interaction with the basement membrane via
the basal surface of its polarized membrane, undergo a wide array of molecular and
cellular changes which enable them to transition to a mesenchymal phenotype.
Phenotypic traits of mesenchymal cells include enhanced motility, increased invasive
capacity, resistance to apoptosis, and the production of ECM components 42. Cells
progressing through EMT are characterized by the down-regulation of epithelial markers
like E-cadherin and claudin-1, and the up-regulation of mesenchymal markers such as
N-cadherin and vimentin43. EMT is under strict regulation by several gene products, with
the most well characterized being Snail, Slug, Twist1, ZEB1, and ZEB2 44. Like many
other carcinomas, EMT contributes to drug resistance and the metastatic nature of
tumors in patients diagnosed with HCC.
EMT TRANSCRIPTION FACTORS
Snail and Slug are zinc-finger proteins belonging to the Snail family of transcription
factors45. Snail family transcription factors are able to directly bind directly to the
promoter region of the CDH1 gene, which codes for E-cadherin, and repress its
expression, while simultaneously up-regulating the expression of pro-invasive genes
such as vimentin, fibrinogen, and matrix metalloproteinases46. Snail and Slug
expression can be induced by hypoxic conditions and Transforming Growth Factor-β
(TGF-β) activity, both of which are usually enhanced during EMT 47.
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Twist1 is a basic helix-loop-helix transcription factor. The basic/helix-loop-helix domain
of Twist1 transcription factor allows it to bind DNA directly and facilitates its ability to
enhance expression of N-cadherin and repress the expression of E-cadherin during
EMT48. Up-stream and down-stream signaling pathways related to Twist1 expression
are not fully understood, however, there are studies that report that Twist1 expression is
enhanced by classical EMT-inducing pathways during fetal development, inflammation,
and carcinogenesis. As an example, TGF-β/Ras activated MAPKs have been shown to
significantly increase Ser68 phosphorylation of Twist1, leading to increased stabilization
and higher Twist1 protein levels in breast cancer cells49. Twist1 expression in cancer
correlates with increased invasive capacity, metastasis, tumor aggressiveness,
recurrence, and poor survival outcomes45.
ZEB1 and ZEB2 are members of the zinc finger transcription factor family of proteins.
ZEB1 is structurally composed of 7 zinc finger domains and one homeodomain, with
ZEB2 having an additional zinc finger domain50. The homeodomains of these
transcription factor proteins allow them to bind to specific regulatory regions of target
genes, such as E-cadherin and vimentin, and either repress or enhance gene
expression51, 52. ZEB1 and ZEB2 are induced by innate EMT factors like hypoxic
conditions, inflammatory cytokines, and the TGF-β signaling pathway53.
CANCER STEMNESS
The cancer stem cell theory proposes that tumors are composed of an organized
hierarchy of heterogeneous cell populations and, like somatic cells, a specific
subpopulation known as cancer stem cells (CSC) are responsible for tumor formation,
growth, and maintence54. The stochastic model of tumor development contrasts with the
9

CSC model, and theorizes that somatic cell populations acquire multiple mutations over
many generations culminating in tumor heterogeneity, and that all mutant cells are
capable of self-renewal and tumorigenesis55 (Fig2).
CSCs are thought to be transformed progenitor cells and all non-CSCs are called the
derived population cells (DC) which are the result of multi-lineage differentiation from
CSCs56. The main phenotypic traits possessed by CSCs are limited differentiation (via
asymmetric division), self-renewal (via symmetric division), and altered proliferative
capacity (mostly quiescent, but can rapidly divide when proper microenvironment stimuli
are present) 57-59. In addition to tumor initiation and maintenance, CSCs are believed to
play significant roles in cancer cell metastasis, multi-drug resistance (MDR), and tumor
recurrence60. In the case of HCC, tumors develop from mutant primary liver
hepatocytes, not progenitor cells, and the cell population responsible for tumor
formation and maintenance are known as the tumor initiator cells (TIC).
Development of therapies that are cable of reducing stemness or even eliminating the
CSC populations are currently underway. However, targeting CSCs has proven to be a
difficult and complex task. This is because CSCs activate signaling pathways and
display cell surface markers, such as CD133, CD44, and EpCAM, similar to normal
somatic stem cells. This makes it somewhat difficult to develop novel therapies against
the CSC population that do not disrupt or kill somatic stem cells and non-dividing cells61.
VIRUS VECTORS IN GENE THERAPY
Gene therapy is described as the experimental technique of transplanting genetic
material into cells with the goal of replacing missing genes or reducing aberrant
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expression of genes, in order to alter a disease phenotype. The first successful
application of gene therapy was in a clinical trial for children with severe combined
immunodeficiency (SCID) in 199062. Since then, it has grown increasingly popular with
the technique having been refined over time. Currently, viral vectors are employed as a
viable application for treating single gene hereditary diseases, infections, and cancers 63.
Human adenoviruses are DNA viruses belonging to the genus Mastadenovirus, with 51
genetically distinct serotypes64. Currently, adenovirus vectors used in therapeutic
settings are replication deficient, having had E1 (replication) and E3 (immune response
evasion) proteins removed during manufacturing and attenuation 65. Adenovirus is one of
the most common vectors used for gene transfer. This is mainly due to their unique
tropism which allows them to infect many different human tissues, ability to infect both
dividing and non-dividing cells, high titer acquisition, large transgene capacity, and
efficient transgene expression66. Additionally, adenovirus vectors, unlike retrovirus
vectors, do not integrate their DNA into host cell genome upon infection, preventing
mutagenesis and the development of genomic irregularities during treatment 67.
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CHAPTER 2
MATERIALS & METHODS

Cell culture conditions
Hep3B cells were obtained from American Type Culture Collection (Manassas, VA);
HepG3 and HuH-7 cells were kindly provided by Dr. Paul Dent. HuH-7 and HepG3 were
grown in Dulbecco’s Modified Eagle Media (DMEM) containing 10% (v/v) fetal bovine
serum and 1% penicillin/streptomycin. Human HCC cell line Hep3B was grown in
Minimum Essential Media (MEM) alpha containing 10% (v/v) fetal bovine serum, 1%
penicillin/streptomycin, 1% non-essential amino acids, and 1% sodium pyruvate. All
cells cultures were maintained at 37oC with 5% CO2.
Adenovirus Infection
Adenovirus vectors were purchased from Vector Biolabs. All adenovirus vectors were
human adenovirus serotype 5 with attenuation of E1 and E3 proteins. Adenovirus-CMVRNAi-GFP (Ad.RNAi) encodes a scrambled RNAi sequence under the U6 promoter with
an eGFP-expression cassette under the CMV promoter. Adenovirus-GFP-U6-SND1shRNA (Ad.SND1sh) encodes human SND1 shRNA under the U6 promoter with an
eGFP-expression cassette under the CMV promoter. Adenovirus containing media for
infection was made by diluting concentrated adenovirus vector stocks in serum-free
DMEM containing 1% penicillin/streptomycin, to the desired multiplicity of infection
(MOI) based on the number of cells being infected. Adenovirus in media solution was
administered to and infected for two hours at 37oC with 5% CO2. The adenovirus
solution being removed and DMEM with 10% FBS and 1% penicillin/streptomycin was
12

added to the plate/well, and cells were incubated at 37oC with 5% CO2 for 24 hours
(experimental assays) or 48 hours (lysate collection).

Western blotting
Cells were washed twice with PBS and lysed with 250 ul of 1.5% n-dodecyl-D-maltoside
(DDM) lysis buffer. Cellular debris was removed by centrifugation at 15,000 rpm for 15
minutes at 4oC. Protein concentrations were determined by Bradford protein assay.
Lysates containing equal amounts of protein were resolved in 10% SDS-PAGE and
transferred to nitrocellulose membranes. Membranes were blocked for 1 hour at room
temperature (RT) in blocking buffer ( 5% nonfat milk powder in TBST: 10 mm TRIS-HCL
(pH 8.0), 150 mm NaCl, 0.05% Tween 20), incubated overnight at 4oC with respective
primary antibodies diluted in blocking buffer. Membranes were washed three times with
TBST (10 min, RT), incubated in respective secondary antibodies for 1 hour at RT, and
then washed with TBST thrice more (10 min, RT). Enhanced Chemiluminescence (ECL)
detection reagents were used to detect proteins of interest, with GAPDH being used as
an internal control.
qRT-PCR
Purified RNA was extracted from cells with the Zymo Research Direct-zol RNA MiniPrep
Plus kit. 2 μg sample of extracted RNA was added to master mix (2 ul 10x buffer, 2 ul
random primers, 0.8 ul dNTP, 1 ul RNase out, and 1 ul of Reverse Transcriptase) to
synthesize cDNA. 2.5 ul of cDNA sample was then added to 25 ul of Taqman master
mix, 20 ul of RNase free H2O, and 2.5 ul of probe. Two 20 ul aliquots of this mixture
13

then underwent PCR. SND1 and GAPDH probes were used, with the latter serving as
an internal control.
Immunofluorescence
For Immunofluorescence assay, cells were seeded on Millicell EZ slide (Millipore) with a
density of 2.5x104 cells/mL in each chamber. Cells were infected with adenovirus, as
described above, and incubated for 24 hours at 37oC with 5% CO2. Cells were then
fixed with 4% paraformaldehyde for 20 minutes at RT, washed thrice with PBS,
permeabilized with 0.1% Triton in PBS for 5 minutes at RT, and washed with PBS three
more times. Next, the cells were blocked with 200 ul of blocking buffer (1% Bovine
Serum Albumin and 10% Goat serum in PBS) for 2 hours at RT and incubated with
primary antibody diluted in blocking buffer overnight at 4oC. After washing with PBS,
cells were then incubated with fluorochrome conjugated secondary antibodies (1:400
dilution). Images were captured using a confocal microscope (LSM700) provided by
MCV microscopy core. Uninfected cells processed according to the above-mentioned
protocol, with the exception of primary antibody incubation, were used as a negative
control in this assay.
MTT Assays
2000 cells were plated in a 96-well plate and infected 24 hours later. At 48, 96, and 144
hours post infection 10% (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide)
(MTT) in media was administered to the cells. After 4 hours of incubation, an equal
volume of 10% sodium dodecyl sulphate (SDS) in H2O was added. The plates were
incubated overnight. Absorbance was measure at 600 nm.
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In vitro Wound Healing Assays
A wound healing scratch assay was used to evaluate cell migration. Two-well silicon
inserts (IBIDI, Martinsried, Germany) were individually placed inside the chambers of a
12-well plate. Cells were infected with adenovirus, as described above, and incubated
for 24 hours. 70 μls of a suspension containing 5x105 cells/ml were seeded into each
side of the insert and incubated overnight at 3 7oC with 5% CO2. After the cells have
adhered, the insert was removed, forming a 500 μm lesion in between the cells. The
scratched monolayer images were captured at 0, 24, and 48 hours after wounding.
Wound healing was measured and quantified using MetaVi Labs Wound Healing
analysis software (IBIDI, Martinsried, Germany).
Invasion Assays
BioCoat cell culture inserts with an 8-μ-porosity polyetyleneterapthalate membrane
coated with Matrigel basement membrane matrix (100 μg/cm 2) were used to measure
the invasive capacity of cells. Inserts were rehydrated in 24-well plates with serum free
DMEM (0% FBS) for 2 hours at 37oC with 5% CO2. The lower chamber (well) in the 24well plate was filled with 0.75 ml of 10% FBS in DMEM. Cells were infected with
adenovirus, as described above, an incubated for 24 hours. 2.5x104 cells were
suspended in 0.5 mL of serum free DMEM (0% FBS) and seeded in the upper
compartment (6.25 mm membrane size) of the insert. The inserts were placed in a 24well plate and incubated for 22 hours at 37oC with 5% CO2. Inserts were then removed,
fixed, and stained using the Diff-Quick staining kit. Non-invasive cells were scrubbed
away using a cotton swab, and invasion was determined by counting the number of
cells that migrated to the lower side of the filter with a microscope at 100x magnification.
15

Statistical Analysis
Results were checked for statistical significance using the student T-test with a onetailed hypothesis, the one-way ANOVA test, and the two-way ANOVA test. A P value of
<0.05 was considered as statistically significant.
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CHAPTER 3
RESULTS

Adenovirus vectors can efficiently infect Human HCC cells
HCC cell lines, HepG3, HuH-7, and Hep3B, were either uninfected (control), infected
with 100 MOI of Ad.RNAi (virus control), or infected with 100 MOI of Ad.SND1sh
(treatment). Both adenoviruses contain an eGFP-expression cassette under the CMV
promoter incorporated into their vector constructs. GFP fluorescence was examined in
control and adenovirus-infected cells from all three HCC cell lines (Fig. 3a). No GFP
expression was observed in control cells. GFP expression was observed in more than
90% of cells observed in both Ad.RNAi- and Ad.SND1sh-infected groups indicating that
these adenovirus vectors can effectively deliver transgenes to HCC cells when
inoculated at 100 MOI. A Western blot was performed to quantify the levels of GFP
being produced in control, Ad.RNAi-, and Ad.SND1sh-infected HCC cells (Fig. 3b). The
GFP levels showed variability in the 3 HCC cell lines, with HepG3 showing the highest
expression indicating a high degree of adenovirus tropism in this cell line. This data
shows that the adenovirus vectors are capable of infecting human HCC cells, however,
the rate of the viral infection appears to differ depending on the cell line used.
Ad.SND1sh infection reduces SND1 in HCC cells
Ad.SND1sh-mediated knockdown of SND1 was confirmed via immunofluorescence (IF)
in HuH-7 cells, and by Western blot and qRT-PCR in all 3 HCC cell lines. IF of HuH-7
cells showed that Ad.SND1sh-infected cells expressing high GFP levels (top and
bottom arrows of Ad.SND1sh row) also expressed reduced levels of SND1, which
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indicated that Ad.SND1sh-infection can effectively knockdown SND1 in HCC cells (Fig.
4a). There was no observale difference is SND1 levels in uninfected cells (bottom arrow
of Ad.RNAi row) or cells infected with Ad.RNAi (top arrow of Ad.RNAi row) (Fig. 4a).
Western blot of protein lysates collected from control and adenovirus-infected HCC cells
showed a noticeable reduction in SND1 protein levels in cells infected with Ad.SND1sh
compared to Ad.RNAi-infected cells (Fig. 4b). These effects were shown to be
statistically significant upon quantification of image densitometry (Fig. 4c). The results of
qRT-PCR using RNA from control, Ad.RNAi-, and Ad.SND1sh-infected cells showed a
reduction of about 95% in SND1 mRNA levels in Ad.SND1sh-infected cells compared to
control and Ad.RNAi-infected cells (Fig. 4d).
Infection with Ad.SND1 does not affect proliferation in HCC
MTT assay was performed on control and adenovirus-infected HCC cells to determine if
SND1 knockdown affected cellular proliferation. of HCC cells inoculated at 100 MOI
showed potential cytotoxic effects in cells after an extended period of exposure (>72
hours) to adenovirus vectors (Fig 5a, b, c). No consistent statistically significant
changes in cellular proliferation were observed in Ad.SND1sh-infected cells when
compared to Ad.RNAi-infected cells.
Ad.SND1sh-infection inhibits migration in HCC cells
In vitro wound healing assay was performed on control and adenovirus-infected HCC
cells to determine if SND1 knockdown affected cellular migration. HepG3 cells
inoculated with 50 MOI of Ad.SND1sh showed reduced migratory capacity at 24 hours
and at 48 hours compared to Ad.RNAi-infected cells (Fig. 6a). HuH-7 cells inoculated
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with 50 MOI of Ad.SND1sh showed reduced migratory capacity at 24 hours and 48
hours compared to Ad.RNAi-infected cells (Fig. 6b). Hep3B cells inoculated with 25 MOI
of Ad.SND1sh showed reduced migratory capacity at 24 hours and 48 hours compared
to Ad.RNAi-infected cells (Fig. 6c). Using a two-way ANOVA test with unweighted mean
analysis showed that in HepG3 and Hep3B cells treatment (p<0.0001), independent of
time (p=0.2779 and p=0.9204, respectively), was statistically significant in reducing
cellular migration (Fig. 6d, f). In HuH-7 cells, both treatment and time were found to be
statistically significant (p=0.0113) in reducing cellular migration (Fig. 6e).
Ad.SND1sh-infection inhibits invasion in HCC cells
A Matrigel invasion assay was performed on control and adenovirus-infected HCC cells
to determine if SND1 knockdown affected cellular invasion. After fixing and staining of
Matrigel inserts, reductions in the number of cells per field were observed in
Ad.SND1sh-infected HCC cells compared to Ad.RNAi-infected cells (Fig. 7a,b).
Quantification and statistical analysis using a one-way ANOVA for repeated
measurements showed that HepG3 (p= 0.00873) and HuH-7 (p= 0.00474) cells infected
with Ad.SND1sh had a significant reduction in the number of invading cells compared to
Ad.RNAi-infected cells (Fig. 7 c,d).
Ad.SND1sh-infection reduces expression of mesenchymal markers in HCC cells
Western blot was performed to determine the levels of EMT markers in control and
adenovirus-infected HCC cells (Fig. 8a). Changes in EMT marker expression were
shown to be statistically significant upon quantification of image densitometry (Fig. 8b).
Ad.SND1sh-infected HepG3 and HuH-7 cells showed decreased levels of mesenchymal
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marker N-Cadherin when compared to Ad.RNAi-infected cells. No change in epithelial
marker E-Cadherin observed in Ad.SND1sh-infected cell compared to Ad.RNAi-infected
cells. The levels of transcription factors known to regulate EMT, such as Twist, Snail,
and Slug, were also probed (Fig. 8a). Twist and Snail levels were significantly reduced
in Ad.SND1sh-infected HuH-7 cells, while Slug was significantly reduced in HepG3 and
HuH-7 cell lines infected with Ad.SND1sh compared to Ad.RNAi-infected cells (Fig. 8b).
Hep3B appears to display reduced levels of Slug protein, however, statistical analysis
comparing Ad.RNAi- and Ad.SND1sh-infected Hep3b cells determined the p value to be
0.063, which is extremely close to the threshold of statistical significance (<0.05) used in
this study. No expression of Snail was detected in Hep3B cells.

Ad.SND1sh-infection reduces AFP and CD133 expression in HCC cells
Western blot was performed to check the levels of HCC marker α-fetoprotein (AFP) and
tumor initiating cell marker CD133 in control and adenovirus-infected HCC cells (Fig.
9a). Changes in AFP and CD133 protein levels were shown to be statistically significant
upon quantification of image densitometry (Fig. 9b). Ad.SND1sh-infected cells from all
three HCC cell lines showed a significant reductions in protein levels of AFP and CD133
when compared to Ad.RNAi-infected cells (Fig. 9b).
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CHAPTER 4
FIGURES

Figure 1: A schematic detailing the various functions of SND1 and how it contributes to
oncogenesis.
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Figure 2: A schematic representation of the stochastic and cancer stem cell model
theories of tumor development.
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Figure 3: Adenovirus vectors can efficiently infect human HCC cells.
Adenovirus infection is detectable via eGFP-cassette expression. (a) A set of
representative fluorescent confocal micrographs and (b) a western blot of control,
Ad.RNAi, and Ad.SND1sh-infected cells, where eGFP expression is only observed in
adenovirus-infected cells.
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Figure 4: Ad.SND1sh reduces SND1 in HCC cell lines.
(a) A set of representative fluorescent confocal micrographs from an
immunofluorescence assay probing for SND1 expression in Ad.RNAi-, Ad.SND1shinfected, and negative control HuH-7 cells. The top arrow in Ad.RNAi indicates a GFPpositive (infected) cell and the lower arrow shows a GFP-negative (uninfected) cell. The
arrows in Ad.SND1sh indicate two GFP-positive (infected) cells. (b) A western blot
probing for SND1 protein in control and adenovirus-infected HCC cells. (c) A
representative bar graph of SND1 blot densitometry in HCC cells. (d) mRNA expression
levels of SND1 quantified by q-RT-PCR in control and adenovirus-infected infected
HCC cells. *P< 0.05, Student’s t test.
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Figure 5: Ad.SND1sh does not affect proliferation in HCC cells.
Bar graphs representing the quantification of cell survival data from MTT assays of
control and adenovirus-infected (a) HepG3 cells (b) HuH-7 cells (c) and Hep3B cells at
24, 48, 96, and 144 hours post infection. *P< 0.05, Student’s t test.
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Figure 6: Ad.SND1sh-infection inhibits migration in HCC cells.
Pictomicrographs of in vitro wound healing assay in adenovirus-infected (a) HepG3 (b)
Huh-7 and (c) Hep3B cells at 0, 24, and 48 hours post wounding. Bar graphs
representing measurements of the scratch open area (lesion width) observed in
pictomicrographs of adenovirus-infected (d) HepG3 (e) Huh-7 and (f) Hep3B cells. *P<
0.05, Two-Way ANOVA Test-Unweighted.
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Figure 7: Ad.SND1sh-infection inhibits invasion in HCC cells.
Pictomicrographs of Matrigel invasion assay in adenovirus-infected (a) HepG3 and (b)
Huh-7 cells. Bar graphs representing the number of stained invading cells per field
observed in pictomicrographs of adenovirus infected (c) HepG3 and (d) HuH-7 cells.
*P< 0.05, One-Way ANOVA for Repeated Measures.
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Figure 8: Ad.SND1sh-infection reduces expression of mesenchymal markers in HCC
cells. (a) A western blot showing EMT markers N-Cadherin, E-cadherin, Twist, Snail,
and Slug protein levels in control and adenovirus-infected HCC cell lines. (b) Bar graphs
representing densitometry of mesenchymal markers from western blot of control and
adenovirus-infected HCC cells. *P< 0.05, Student’s t test.
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Figure 9: Infection with Ad.SND1sh reduces AFP and CD133 expression in HCC cells.
A western blot showing tumor cell initiator marker CD133 and HCC marker Alphafetoprotein (AFP) levels in control and adenovirus-infected HCC cell lines. (b) Bar
graphs representing densitometry of CD133 and AFP from western blot of control and
adenovirus-infected HCC cells. *P< 0.05, Student’s t test.
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CHAPTER 5
DISCUSSION AND FUTURE DIRECTIONS
SND1 is an established oncogene that has been shown to be overexpressed in many
organ cancers including HCC. In HCC, SND1 is over expressed to such a significant
extent that its protein level abundance has been seen to positively correlate with
increased tumor progression and poor survival outcomes in patients. These findings
indicate that SND1 inhibition might be a potential treatment strategy for advanced HCC.
Therapeutic options available for treating advanced HCC are severely limited, especially
in patients diagnosed with late stage development where liver resection is no longer a
viable option. In fact, HCC is usually detected at late stages and currently Sorafenib and
regorafenib are the only FDA approved chemotherapy drugs available to patients in this
situation. Recently anti-PD-1 antibody, Nivolumab, has been approved for HCC
treatment by FDA with limited therapeutic outcome. To that end, we are seeking to
develop additional therapies that may potentially inhibit or reduce carcinogenesis in
human HCC cells.
Recent studies involved in improving cancer treatment have been moving toward a
“targeted gene therapy” approach, where the expression of oncogenes and tumor
suppressor genes (TSGs) are altered in ways that reduce the malignancy of cancer
cells. The present study indicates that targeting the expression of SND1 oncogene in
human HCC cell lines holds promise as a potential HCC therapy. It was decided that an
adenovirus vector would serve as the best delivery system for SND1 targeted gene
therapy. This is because, unlike many viral vector systems, adenoviruses do not
integrate their DNA into the host cell genome. Though inability to integrate means that
the desired alterations to SND1 expression are robust, yet transient, it also means that
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this system avoids induction of mutations/indels due to sporadic viral genome site
integration. Transposon induced mutagenesis has been shown to impact EMT and
chemotherapy resistance in HCC cells68, so it is best to avoid integrative viruses if
possible. Furthermore, attenuated human adenovirus vectors are capable of carrying
large transgenes, infecting a wide-range of cells and can easily be propagated to a high
titer. These features are what make adenovirus vectors a promising mode of delivery in
our study. Additionally, three distinct immortalized HCC cell lines were used in this study
to observe the potential of treatment variability associated with cellular heterogeneity.
HepG3 cells are derived from a liver hepatocellular carcinoma of a 15-year-old
Caucasian male, with wild type p53 expression, and stably express duck HBV
transgene. HuH-7 cells are a well differentiated hepatocellular carcinoma cell line taken
from a liver tumor in a 57-year-old Japanese male, express mutant p53, and have no
viral background. Hep3B cells originate from an 8-year-old African American male, lack
p53 expression, and the patient was determined to be HBV positive. Data from this
study shows that adenovirus vectors effectively infect human HCC cells in vitro and that
the therapeutic results of adenovirus-mediated knockdown of SND1 are consistent
across heterogeneous cell populations.
shRNA knockdown of SND1 was highly effective, with roughly 95% of SND1 mRNA
being reduced when cells were infected at 100 MOI. 100 MOI was determined to be the
standard for capturing the effects of Ad.SND1sh infection of HCC cell lines. This is
because significant changes at the protein level were seen via Western blot with SND1,
but not with any of the other proteins of interest when using lysates from cells infected
at lower MOIs. Additionally, a high f MOI was needed because prolonged exposure to
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the virus (>72 hours) showed signs of cytotoxicity in HepG3 and Hep3B HCC cell lines.
This may explain why the MOIs used for the wound healing and Matrigel invasion
assays had to be altered in order to get accurate results that were independent of
virus’s toxic effects. Statistical analyses comparing data from MTT assay of control,
Ad.RNAi-, and AdSND1sh-infected HCC cells showed that there was no consistent
statistically significant differences in proliferation associated with adenovirus mediated
of SND1 in these HCC cell lines.
Changes in cellular migration and invasion are phenotypic attributes associated with
epithelial mesenchymal transition (EMT). EMT is as hallmark feature of carcinogenesis
which grants cancer cells the ability to break down and migrate through the basement
membrane, invade the blood stream or lymphatic system, and metastasize in distant
tissues. To assess if knockdown of SND1 reverses EMT in infected human HCC cells,
cell lysates were probed for EMT markers: N-Cadherin and E-Cadherin. A reduction in
N-Cadherin at the protein level was observed in Ad.SND1sh-infected HepG3 and HuH-7
cells, yet, the protein levels of E-cadherin remained unchanged. Cadherin switching is a
common occurrence in carcinogenic cells undergoing EMT but has yet to be fully
understood in context of HCC. Analysis of tissue samples from patients diagnosed with
HCC found that there was no significant indication of cadherin switching, with only 5 of
the 63 patient samples in the cohort displaying strong N-Cadherin and reduced ECadherin IHC staining in HCC tumor cell membrane69. This prompted the need to
analyze transcription factors that regulate EMT, such as Snail, Slug, and Twist in order
to determine which protein(s) were responsible for this change in EMT phenotype. Snail
and Twist proteins were reduced in Ad.SND1sh-infected cells, while Slug was
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universally down regulated in all HCC cell lines with SND1 knockdown. Based on this
data, we can conclude that adenovirus-mediated knockdown of SND1 reduces Slug
expression in HCC cells, leading to a decrease in N-Cadherin, which causes cells to
lose mesenchymal features resulting in reduced migratory and invasive capacity. Also,
certain HCC phenotypes may also display reductions in Snail and Twist protein levels.
We believe this may be the result of genetic heterogeneity in HCC cell phenotypes.
Recent studies have been published linking EMT to the generation of stem cell like
properties in cancer cells70. A similar study found that when IHC was performed on 27
HCC patient samples, EMT markers E-Cadherin and N-Cadherin were down regulated
63% and upregulated in 81%, respectively, of patient samples. Also, of note was that
78% of those patient samples were found to have significant upregulation of TIC marker
CD13371. To assess if SND1 knockdown affects cancer stemness in HCC cells, lysates
from control and adenovirus-infected cells were probed for TIC marker CD133 and HCC
marker α-fetoprotein (AFP). A reduction in both CD133 and AFP was observed in
Ad.SND1sh-infected cells from all three HCC cell lines. This finding is significant
because Slug overexpression has been shown to enhance CD133 expression in the
HCC cell line HepG272. In addition, CD44+ CD133+ HCC cells have been found to
correlate with enhanced AFP expression and poor differentiation 73. Based on the
established literature and data obtained from this study, it can be inferred that SND1
knockdown reduces Slug expression, which in turn reduces CD133 and AFP protein
expression in human HCC cells.
Further investigation is needed to better understand how adenovirus-mediated
knockdown of SND1 leads to decreased Slug protein levels in HCC cell lines. Since no
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significant changes were detected in E-Cadherin protein levels of Ad.SND1sh-infected
HCC cells, it would be recommended to probe for other EMT other mesenchymal
markers, such as Vimentin, Fibronectin, and Laminin-5. Probing for these proteins may
prove to further distinguish how reduced SND1 expression affects HCC cells,
particularly in the case of Hep3B cells where Ad.SND1sh-infection significantly reduced
migration but had no significant effect on N-Cadherin protein levels. Rhodamine
phalloidin staining of Ad.SND1sh HCC cells may display a difference in actin
organization, which is expected to be altered with reduced migratory and invasive
capacity. With AFP and CD133 reduction being confirmed with SND1 knockdown, tumor
sphere formation capacity and drug resistance need to be assessed to successfully
validate diminished TIC phenotype in human HCC cells. Once the phenotypes and
molecular pathways associated with adenovirus-mediated knockdown of SND1 have
been fully investigated in vitro, this gene therapy system should be assessed using
nude mice to determine its efficacy in vivo.
In conclusion, we have shown that an adenovirus vector system is efficient in delivering
targeted gene therapy to HCC cells in vitro, with adenovirus-mediated knockdown of
SND1 resulting in reversal of EMT and reduction in liver cancer stem cell markers AFP
and CD133 via reduction of Slug protein expression.

36

REFERENCES
1.
2.
3.

4.

5.
6.
7.

8.

9.

10.
11.

12.
13.
14.

15.

Bosch FX, Ribes J, Cleries R, Diaz M. Epidemiology of hepatocellular
carcinoma. Clin Liver Dis. 2005;9:191–211.
Mittal S, El-Serag HB. Epidemiology of HCC: Consider the
Population. Journal of clinical gastroenterology. 2013;47(0):S2-S6.
Davila JA, El-Serag HB. The Rising Incidence of Hepatocellular Carcinoma in
the United States: an Update. Gastroenterology. 2012;142(suppl 1):S914–
S914.
Colombo M, de Franchis R, Del Ninno E, Sangiovanni A, De Fazio C,
Tommasini M, Donato MF, Piva A, Di Carlo V, Dioguardi N. Hepatocellular
carcinoma in Italian patients with cirrhosis. N Engl J Med. 1991 Sep
5;325(10):675-80.
Schuppan, Detlef and Nezam H Afdhal. “Liver cirrhosis” Lancet (London,
England) vol. 371,9615 (2008): 838-51.
Parkin DM. The global health burden of infection-associated cancers in the
year 2002. Int J Cancer. 2006 Jun 15;118(12):3030-44.
Schinzari V., Barnaba V., Piconese S. Chronic hepatitis B virus and hepatitis
C virus infections and cancer: Synergy between viral and host factors. Clin.
Microbiol. Infect. 2015;21:969–974. doi: 10.1016/j.cmi.2015.06.026.
Rapicetta M, Ferrari C and Levrero M: Viral determinants and host immune
responses in the pathogenesis of HBV infection. J Med Virol 67: 454-457,
2002.
Leonardi GC, Candido S, Cervello M, Nicolosi D, Raiti F, Travali S,
Spandidos DA, Libra M. The tumor microenvironment in hepatocellular
carcinoma (review). Int J Oncol. 2012 Jun;40(6):1733-47.
Epidemiology of viral hepatitis and hepatocellular carcinoma.
Gastroenterology. 2012;142(6):1264-1273.e1.
Perz J.F., Armstrong G.L., Farrington L.A., Hutin Y.J., Bell B.P. The
contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis
and primary liver cancer worldwide. J. Hepatol. 2006;45:529–538. doi:
10.1016/j.jhep.2006.05.013
Lemon S.M., McGivern D.R. Is Hepatitis C Virus Carcinogenic?
Gastroenterology. 2012;142:1274–1278. doi: 10.1053/j.gastro.2012.01.045.
Lemon S.M., McGivern D.R. Is Hepatitis C Virus Carcinogenic?
Gastroenterology. 2012;142:1274–1278. doi: 10.1053/j.gastro.2012.01.045.
Ikeda K, Saitoh S, Suzuki Y, et al. Disease progression and hepatocellular
carcinogenesis in patients with chronic viral hepatitis: a prospective
observation of 2215 patients. J Hepatol. 1998;28:930–938.
Welzel TM, Graubard BI, Zeuzem S, et al. Metabolic syndrome increases the
risk of primary liver cancer in the United States: a study in the SEERMedicare database. Hepatology. 2011;54:463–471.

37

16.

17.

18.

19.

20.

21.

22.

23.

24.

25.

26.
27.

Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53
gene in hepatocellular carcinoma from southern Africa. Nature.
1991;350:429–431.
Olsen SK, Brown RS, Siegel AB. Hepatocellular carcinoma: review of current
treatment with a focus on targeted molecular therapies. Therap Adv
Gastroenterol. 2010 Jan;3(1):55-66. doi: 10.1177/1756283X09346669.
Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F,
Montalto F, Ammatuna M, Morabito A, Gennari L. Liver transplantation for the
treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl
J Med. 1996 Mar 14;334(11):693-9.
Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, Zironi G, Piscaglia F,
Gramantieri L, Zanetti M, Sherman M. Surveillance programme of cirrhotic
patients for early diagnosis and treatment of hepatocellular carcinoma: a cost
effectiveness analysis. Gut. 2001 Feb;48(2):251-9.
Lencioni RA, Allgaier HP, Cioni D, Olschewski M, Deibert P, Crocetti L, Frings
H, Laubenberger J, Zuber I, Blum HE, Bartolozzi C. Small hepatocellular
carcinoma in cirrhosis: randomized comparison of radio-frequency thermal
ablation versus percutaneous ethanol injection. Radiology. 2003
Jul;228(1):235-40.
Contratto M, Wu J. Targeted therapy or immunotherapy? Optimal treatment in
hepatocellular carcinoma. World J Gastrointest Oncol. 2018 May
15;10(5):108-114.
Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., et al.
(2008b) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:
378–390
Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M,
Yokosuka O, Rosmorduc O, Breder V, et al. Regorafenib for patients with
hepatocellular carcinoma who progressed on sorafenib treatment
(RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet. 2017;389:56–66.
El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim TY,
Choo SP, Trojan J, Welling TH Rd, Meyer T, Kang YK, Yeo W, Chopra A,
Anderson J, Dela Cruz C, Lang L, Neely J, Tang H, Dastani HB, Melero I.
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate
040): an open-label, non-comparative, phase 1/2 dose escalation and
expansion trial. Lancet. 2017;389:2492–2502.
Voeghtly LM, Mamula K, Campbell JL, Shriver CD and Ellsworth RE:
Molecular alterations associated with breast cancer mortality. PLoS One.
7:e46814, 2012.
Jenkins RB, Qian J, Lee HK, et al: A molecular cytogenetic analysis of 7q31
in prostate cancer. Cancer Res. 58:759–766, 1998.
Glukhova L, Lavialle C, Fauvet D, et al: Mapping of the 7q31 subregion
common to the small chromosome 7 derivatives from two sporadic papillary
38

28.

29.

30.

31.
32.

33.

34.

35.

36.

37.

38.
39.

40.

renal cell carcinomas: increased copy number and overexpression of the
MET proto-oncogene. Oncogene. 19:754–761, 2000.
Li CL, Yang WZ, Chen YP and Yuan HS: Structural and functional insights
into human Tudor-SN, a key component linking RNA interference and editing.
Nucleic Acids Res. 36:3579–3589, 2008.
Callebaut I and Mornon JP: The human EBNA-2 coactivator p100:
multidomain organization and relationship to the staphylococcal nuclease fold
and to the tudor protein involved in Drosophila melanogaster development.
Biochem J. 321:125–132, 1997
Theobald DL, Mitton-Fry RM, Wuttke DS. Nucleic acid recognition by OB-fold
proteins. Annu Rev Biophys Biomol Struct. 2003;32:115-33. Epub 2003 Feb
18.
Ying M, Chen D. Tudor domain-containing proteins of Drosophila
melanogaster. Dev Growth Differ. 2012 Jan;54(1):32-43.
Yoo BK, Santhekadur PK, Gredler R, et al: Increased RNA-induced silencing
complex (RISC) activity contributes to hepatocellular carcinoma. Hepatology.
53:1538–1548. 2011.
Jariwala N, Rajasekaran D, Srivastava J, Gredler R, Akiel MA, Robertson CL,
Emdad L, Fisher PB, Sarkar D. Role of the staphylococcal nuclease and tudor
domain containing 1 in oncogenesis (review). Int J Oncol. 2015
Feb;46(2):465-73.
Tong X, Drapkin R, Yalamanchili R, Mosialos G and Kieff E: The Epstein-Barr
virus nuclear protein 2 acidic domain forms a complex with a novel cellular
coactivator that can interact with TFIIE. Mol Cell Biol. 15:4735–4744, 1995
Paukku K, Yang J and Silvennoinen O: Tudor and nuclease-like domains
containing protein p100 function as coactivators for signal transducer and
activator of transcription 5. Mol Endocrinol. 17:1805–1814, 2003.
Valineva T, Yang J, Palovuori R and Silvennoinen O: The transcriptional coactivator protein p100 recruits histone acetyl-transferase activity to STAT6
and mediates interaction between the CREB-binding protein and STAT6. J
Biol Chem. 280:14989–14996, 2005
Liu X, Dong L, Zhang X, et al: Identification of p100 target promoters by
chromatin immunoprecipitation-guided ligation and selection (ChIP-GLAS).
Cell Mol Immunol. 8:88–91, 2011.
Caudy AA, Ketting RF, Hammond SM, et al: A micrococcal nuclease
homologue in RNAi effector complexes. Nature. 425:411–414, 2003.
Paukku K, Kalkkinen N, Silvennoinen O, Kontula KK, Lehtonen JY. p100
increases AT1R expression through interaction with AT1R 3'-UTR. Nucleic
Acids Res. 2008;36(13):4474-87.
Santhekadur PK, Akiel M, Emdad L, Gredler R, Srivastava J, Rajasekaran D,
Robertson CL, Mukhopadhyay ND, Fisher PB, Sarkar D. Staphylococcal
nuclease domain containing-1 (SND1) promotes migration and invasion via

39

41.

42.

43.

44.

45.

46.

47.

48.

49.

50.

51.

52.

angiotensin II type 1 receptor (AT1R) and TGFβ signaling. FEBS Open Bio.
2014 Apr 1;4:353-61.
Jariwala N, Rajasekaran D, Mendoza RG et al. Oncogenic role of SND1 in
development and progression of hepatocellular carcinoma. Cancer Res 2017;
77: 3306–16
Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal
states: acquisition of malignant and stem cell traits. Nat Rev Cancer.
2009;9:265–273. doi: 10.1038/nrc2620.
S. Bugide, V.K. Gonugunta, V. Penugurti, V.L. Malisetty, R.K. Vadlamudi, B.
Manavathi, HPIP promotes epithelial-mesenchymal transition and cisplatin
resistance in ovarian cancer cells through PI3K/AKT pathway activation. Cell
Oncol 40, 133–144 (2017
Samatov TR, Tonevitsky AG, Schumacher U. Epithelial-mesenchymal
transition: focus on metastatic cascade, alternative splicing, non-coding RNAs
and modulating compounds. Mol Cancer. 2013;12(1):107. Published 2013
Sep 23. doi:10.1186/1476-4598-12-107
Sánchez-Tilló E, Liu Y, de Barrios O, Siles L, Fanlo L, Cuatrecasas M, Darling
DS, Dean DC, Castells A, Postigo A. EMT-activating transcription factors in
cancer: beyond EMT and tumor invasiveness. Cell Mol Life Sci.
2012;69:3429–3456. doi: 10.1007/s00018-012-1122-2.
Peinado H, Marin F, Cubillo E, Stark HJ, Fusenig N, Nieto MA, Cano A. Snail
and E47 repressors of E-cadherin induce distinct invasive and angiogenic
properties in vivo. J Cell Sci. 2004 Jun 1;117(Pt 13):2827-39.
Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial mesenchymal
transitions in development and disease. Cell. 2009;139:871–890. doi:
10.1016/j.cell.2009.11.007.
Qin Q, Xu Y, He T, Qin C, Xu J. Normal and disease related biological
functions of Twist1 and underlying molecular mechanisms. Cell Res.
2012;22:90–106. doi: 10.1038/cr.2011.144.
Hong J, Zhou J, Fu J, He T, Qin J, Wang L, Liao L, Xu J. Phosphorylation of
serine 68 of Twist1 by MAPKs stabilizes Twist1 protein and promotes breast
cancer cell invasiveness. Cancer Res. 2011 Jun 1;71(11):3980-90. doi:
10.1158/0008-5472.CAN-10-2914.
Bürglin TR, Affolter M. Homeodomain proteins: an update. Chromosoma.
2016 Jun;125(3):497-521. doi: 10.1007/s00412-015-0543-8. Epub 2015 Oct
13. Review.
Vandewalle C, Van Roy F, Berx G. The role of the ZEB family of transcription
factors in development and disease. Cell Mol Life Sci. 2009;66:773–787. doi:
10.1007/s00018-008-8465-8
Bindels S, Mestdagt M, Vandewalle C, Jacobs N, Volders L, Noe¨l A, Van
Roy F, Berx G, Foidart JM, Gilles C. Regulation of vimentin by SIP1 in human
epithelial breast tumor cells. Oncogene. 2006;25:4975–4985. doi:
10.1038/sj.onc.1209511.
40

53.

54.

55.

56.

57.

58.
59.

60.

61.
62.
63.
64.
65.

66.

67.

De Craene B, Berx G. Regulatory networks defining EMT during cancer
initiation and progression. Nat Rev Cancer. 2013 Feb;13(2):97-110. doi:
10.1038/nrc3447.
Dalerba P, Cho RW, Clarke MF. Cancer stem cells: models and concepts.
Annu Rev Med. 2007;58:267–84. doi:
10.1146/annurev.med.58.062105.204854.
Jayachandran A, Dhungel B, Steel JC. Epithelial-to-mesenchymal plasticity of
cancer stem cells: therapeutic targets in hepatocellular carcinoma. J Hematol
Oncol. 2016;9(1):74. Published 2016 Aug 30. doi:10.1186/s13045-016-03079
Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U,
Goodell MA, Brenner MK. A distinct “side population” of cells with high drug
efflux capacity in human tumor cells. Proc Natl Acad Sci U S A.
2004;101:14228–33. doi: 10.1073/pnas.0400067101.
Pierce GB, Speers WC. Tumors as caricatures of the process of tissue
renewal: prospects for therapy by directing differentiation. Cancer
Res. 1988;48:1996–2004.
Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and
cancer stem cells. Nature. 2001;414:105–111.
Boman BM, Wicha M, Fields JZ, Runquist O. Symmetric division of cancer
stem cells: a key mechanism in tumor growth that should be targeted in future
therapeutic approaches. J Clin Pharmacol Ther. 2007;81:893–898.
Adorno-Cruz V, Kibria G, Liu X, Doherty M, Junk DJ, Guan D, et al. Cancer
stem cells: targeting the roots of cancer, seeds of metastasis, and sources of
therapy resistance. Cancer Res. 2015;75(6):924–929.
Ajani JA, Song S, Hochster HS, Steinberg IB. Cancer stem cells: the promise
and the potential. Semin Oncol. 2015;(Suppl 1):S3–17.
Gelfand EW. SCID continues to point the way. N Engl J
Med. 1990;322:1741–1743.
Wang YG, Huang F, Cai R, Qian C, Liu XY. Targeting strategies for adenoassociated viral vector. Zhongguo Kexue Tongbao. 2007;52:1590–1599.
Davison A. J., Benko M., Harrach B. (2003). Genetic content and evolution of
adenoviruses. J. Gen. Virol. 84, 2895–2908. 10.1099/vir.0.19497-0
He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified
system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A.
1998;95(5):2509-14.
Wang YG, Huang PP, Zhang R, Ma BY, Zhou XM, Sun YF. Targeting adenoassociated virus and adenoviral gene therapy for hepatocellular
carcinoma. World J Gastroenterol. 2016;22(1):326-37.
Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N,
McIntyre E, Radford I, Villeval JL, Fraser CC, Cavazzana-Calvo M, Fischer A.
A serious adverse event after successful gene therapy for X-linked severe
combined immunodeficiency. N Engl J Med. 2003 Jan 16;348(3):255-6.
41

68.

69.

70.

71.

72.

73.

Kodama T, Newberg JY, Kodama M, et al. Transposon mutagenesis identifies
genes and cellular processes driving epithelial-mesenchymal transition in
hepatocellular carcinoma. Proc Natl Acad Sci U S A. 2016;113(24):E3384-93.
Cho SB, Lee KH, Lee JH, Park SY, Lee WS, Park CH, Kim HS, Choi SK, Rew
JS. Expression of E- and N-cadherin and clinicopathology in hepatocellular
carcinoma. Pathol Int. 2008 Oct;58(10):635-42. doi: 10.1111/j.14401827.2008.02282.x.
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M,
Reinhard F, Zhang CC, Shipitsin M, et al. The epithelial-mesenchymal
transition generates cells with properties of stem cells. Cell. 2008;133:704–
715. doi: 10.1016/j.cell.2008.03.027.
Zhou JN, Zeng Q, Wang HY, Zhang B, Li ST, Nan X, Cao N, Fu CJ, Yan XL,
Jia YL, et al. MicroRNA-125b attenuates epithelial-mesenchymal transitions
and targets stem-like liver cancer cells through small mothers against
decapentaplegic 2 and 4. Hepatology. 2015;62:801–815. doi:
10.1002/hep.27887.
Sun Y, Song GD, Sun N, Chen JQ, Yang SS. Slug overexpression induces
stemness and promotes hepatocellular carcinoma cell invasion and
metastasis. Oncol Lett. 2014;7:1936–1940.
Wang K, Sun D. Cancer stem cells of hepatocellular carcinoma. Oncotarget.
2018;9(33):23306-23314. Published 2018 May 1.
doi:10.18632/oncotarget.24623

42

VITA
Bryan Mckiver was born in Rapid City, South Dakota on the 25th of November 1992. He
graduated high school in 2011. He received his Bachelor of Science degree in Biology
with a chemistry minor from Virginia Commonwealth University, Richmond, Virginia in
2015. He interned and volunteered at the Massey Cancer Center and was a teaching
assistant in the undergraduate immunology course at Virginia Commonwealth
University for a year before enrolling in the Graduate school at Virginia Commonwealth
University.

43

